Brain Scientific (OTCQB: BRSF), a neurology focused medical device and software company, recently announced a collaboration with JelikaLite, a company developing Cognilum(TM), a non-invasive wearable photobiomodulation device that is being developed to increase the well-being of children living with autism, through a clinical trial. In the trial, “Transcranial Photobiomodulation for Reducing Autism Symptoms in Children,” brain treatments for children diagnosed with autism would be delivered through Cognilum, while Brain Scientific’s NeuroEEG, a wireless EEG device, will monitor brain activity. The trial is designed to provide researchers and clinicians an opportunity to potentially uncover new treatment options for reducing the symptoms children with autism experience. “We are delighted to begin this collaboration with JelikaLite,” said Brain Scientific’s Director of Marketing, Irina Nazarova. “Our Neuro EEG solutions have a wide range of applications and helping to monitor children with autism to improve their well-being would be an important step towards a wider adoption of affordable and accessible EEG systems like ours.”
To view the full press release, visit https://ibn.fm/YA4C7
About Brain Scientific
Brain Scientific is a commercial-stage health care company with two FDA-cleared products, providing next-gen solutions to the neurology market. The company’s smart diagnostic devices and sensors simplify administration, shorten scan time and cut costs, allowing clinicians to make rapid decisions remotely and bridge the widening gap in access to neurological care. To learn more about the company’s corporate strategy, devices or for investor relations, visit www.BrainScientific.com.
NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
